Analysis of the HLA-DR gene frequencies in Japanese cases of juveniles rheumatoid arthritis and rheumatoid arthritis by oligonucleotide DNA typing

Okubo, Hiroko; Itou, Katsumi; Tanaka, Shinsuke; Watanabe, Nobuo; Kashiwagi, Noboru; Obata, Fumiya

doi:10.1007/bf00307736

Cited by 27 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are clinical and pathophysiological similarities between pJIA and adult rheumatoid arthritis, as demonstrated by similarities in response to MTX treatment, synovial lymphatic capillary structure, and susceptible human leukocyte antigen (HLA) types [21,22]. A randomized, double-blind, placebo-controlled, phase III trial of tocilizumab in adult rheumatoid arthritis patients confirmed the safety and efficacy of tocilizumab in that disease [12].…”

Section: Discussionmentioning

confidence: 92%

Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis

et al. 2011

View full text Add to dashboard Cite

We evaluated the safety and efficacy of tocilizumab in polyarticular-course juvenile idiopathic arthritis (pJIA) with polyarticular or oligoarticular onset. Patients received 8 mg/kg tocilizumab every 4 weeks in the open-label studies: initial study (to week 12) and then an extension study (at least 48 weeks). Nineteen patients intractable to conventional methotrexate therapy were enrolled. Seventeen patients had polyarticular-onset pJIA; two had oligoarticular-onset pJIA. Mean age was 11.6 years; mean disease duration 5.3 years. American College of Rheumatology Pediatric (ACR Pedi) 30, 50, 70, and 90 response rates, respectively, were 94.7%, 94.7%, 57.9%, and 10.5% at week 12, and 100%, 94.1%, 88.2%, and 64.7% at week 48. Mean disease activity score (DAS28) remained below the remission level (2.6) from week 24. Administration was discontinued in two patients during the extension study because the ACR Pedi 50 response was judged insufficient (one patient) and antitocilizumab antibodies developed (one patient). Adverse events were generally mild, and the four serious adverse events resolved spontaneously or with treatment. In conclusion, tocilizumab showed early and sustained efficacy and tolerability for treating intractable pJIA, which suggests that it is a promising new treatment for this disease.

show abstract

Section: Discussionmentioning

confidence: 92%

Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…It is also known that an association exists between HLA typing and susceptibility of a certain subtype of JRA [18][19][20], especially for HLA-DR4 and the RF-positive polyarticular type of JRA, as known in RA [21][22][23]. The efficacy of MTX therapy in patients with JRA in Japan might differ from that in Caucasians.…”

Section: Discussionmentioning

confidence: 99%

“…The efficacy of MTX therapy in patients with JRA in Japan might differ from that in Caucasians. This might be explained in part by the difference of HLA typing in patients with JRA in Japan [18][19][20]. This might be explained in part by the difference of HLA typing in patients with JRA in Japan [18][19][20].…”

Section: Discussionmentioning

confidence: 99%

Methotrexate therapy for juvenile rheumatoid arthritis in Japan — surveillance with a questionnaire at seven main facilities

Aihara

Imagawa

Katakura

et al. 1999

Japanese Journal of Rheumatology

View full text Add to dashboard Cite

Methotrexate (MTX) therapy is now a main-stream drug for the treatment of patients with rheumatoid arthritis (RA). Similarly, the therapy is being established in the treatment of juvenile rheumatoid arth¡ (JRA). However, little is known about the therapy for JRA in Japan. Therefore, to establish MTX therapy for JRA we investigated the current state of therapy in Japan. In September 1996 a questionnaire about MTX therapy was sent to the main facilities in Japan where members of the Japan Pediatric Rheumatology Association have been treating patients with JRA. From seven main facilities, a total of 56 JRA patients treated with MTX were reported. From this survey, it was revealed that MTX was used frequently for the treatment of patients with JRA in combination with other drugs such as non-steroidal anti-inflammatory drugs and prednisolone. MTX therapy was determined effective in 80% of cases; moreover, this therapy was tolerable in most cases. However, tbere were a few mild adverse effects including hepatotoxicity. Thus, MTX therapy was applied broadly to JRA patients in Japan. The therapy was determined to be more effective than prior medications when combined with other drugs to treat JRA.

show abstract

“…The introduction of DNA typing to HLA typing elucidated the role of HLA in the pathogenesis of RA. HLA-DRB1*0401, DRB1*0404, DRB1*0405 and DRB1*0408 were reported to be associated with RA in Caucasian populations [7, 53, 54, 55]and DRB1*0405 in Japanese [56], Taiwanese [57], Korean [8], Israeli [58], New Zealand-Polynesian [59]and Spanish [12]populations. DRB1*0402 and DRB1*0403 have never been reported to be associated with RA in any ethnic group.…”

Section: Discussionmentioning

confidence: 99%

Association between HLA-DRB1*15 and Japanese Patients with Rheumatoid Arthritis Complicated by Renal Involvement

Tokunaga¹,

Noda²,

Kaneoka³

et al. 1999

Nephron

View full text Add to dashboard Cite

We performed serological phenotyping of HLA antigens in 175 patients with rheumatoid arthritis (RA) with (n = 41) and without (n = 134) renal involvement (RI), and DNA typing of HLA class II alleles in 75 patients. Among the patients with RA, the frequency of serologically determined HLA-DR4 was found to be significantly increased (odds ratio: 1.8, confidence interval: 1.3–2.5, p = 2.4×10^–4). In the patients without RI, the frequency of serological DR4 significantly increased (odds ratio: 2.2, confidence interval: 1.6–3.3, p = 2.6×10^–5). On the other hand, among the patients with RI, a serological determinant, DR15, did significantly increase (odds ratio: 2.7, confidence interval: 0.9–8.4, p = 1.2×10^–3) in comparison to the controls. At the DNA level, we found that the association of Japanese RA patients with serological HLA-DR4 was based on that with a genotype of HLA-DRB1*0405 (odds ratio: 2.4, confidence interval: 1.5–4.0, p = 4.4×10^–4) and also found an association of HLA-DRB1*1501 (odds ratio: 2.8, confidence interval: 1.2–6.6, p = 0.017) with RA patients having RI. Our results confirmed the association of HLA-DRB1*04 with RA over the ethnic barrier at the DNA level. Our results also suggested a distinct genetic effect of HLA-DRB1*1501 in the aspect of the susceptibility of RI in RA.

show abstract

Analysis of the HLA-DR gene frequencies in Japanese cases of juveniles rheumatoid arthritis and rheumatoid arthritis by oligonucleotide DNA typing

Cited by 27 publications

References 24 publications

Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis

Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis

Methotrexate therapy for juvenile rheumatoid arthritis in Japan — surveillance with a questionnaire at seven main facilities

Association between HLA-DRB1*15 and Japanese Patients with Rheumatoid Arthritis Complicated by Renal Involvement

Contact Info

Product

Resources

About